ELICIO THERAPEUTICS INC (ELTX) Stock Price, Quote, News and Overview
NASDAQ:ELTX - Nasdaq - US28657F1030 - Common Stock - Currency: USD
ELTX Quote, Performance and Key Statistics
NASDAQ:ELTX (8/11/2025, 2:15:18 PM)
8.6
-0.6 (-6.52%)
The current stock price of ELTX is 8.6 USD. In the past month the price increased by 13.86%. In the past year, price increased by 115.96%.
ELTX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.66 | 349.09B | ||
| AMGN | AMGEN INC | 13.11 | 153.73B | ||
| GILD | GILEAD SCIENCES INC | 15.48 | 149.07B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.21 | 96.62B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.09 | 59.60B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 57.19B | ||
| ARGX | ARGENX SE - ADR | 68.55 | 38.89B | ||
| ONC | BEONE MEDICINES LTD-ADR | 4.48 | 31.06B | ||
| BNTX | BIONTECH SE-ADR | N/A | 26.18B | ||
| NTRA | NATERA INC | N/A | 21.38B | ||
| INSM | INSMED INC | N/A | 21.18B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 21.05B |
Related stock screener links
About ELTX
Company Profile
Elicio Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of cancer immunotherapies. The company is headquartered in Boston, Massachusetts and currently employs 32 full-time employees. The company went IPO on 2021-02-05. The firm is engaged in developing a pipeline of immunotherapies for the treatment of cancer. The firm provides a platform, amphiphile (AMP) that delivers immunotherapeutics directly to the lymph nodes (brain center) of the immune system. The Company’s clinical and preclinical pipeline includes the lymph node targeted therapeutic cancer vaccines ELI-002, which is being evaluated in a Phase II study, designed to stimulate an immune response against mutant kirsten rat sarcoma (KRAS). Its ELI-007 is being evaluated in a preclinical study for the treatment of mutant v-raf murine sarcoma viral oncogene homolog B1 (BRAF) driven cancers, and ELI-008, is being evaluated in a preclinical study for use in the treatment of mutated tumor protein p53 (TP53) expressing cancers.
Company Info
ELICIO THERAPEUTICS INC
451 D Street, 5Th Floor
Boston MASSACHUSETTS US
Employees: 32
Phone: 18572090050
ELICIO THERAPEUTICS INC / ELTX FAQ
What is the stock price of ELICIO THERAPEUTICS INC today?
The current stock price of ELTX is 8.6 USD. The price decreased by -6.52% in the last trading session.
What is the ticker symbol for ELICIO THERAPEUTICS INC stock?
The exchange symbol of ELICIO THERAPEUTICS INC is ELTX and it is listed on the Nasdaq exchange.
On which exchange is ELTX stock listed?
ELTX stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for ELICIO THERAPEUTICS INC stock?
8 analysts have analysed ELTX and the average price target is 12.75 USD. This implies a price increase of 48.26% is expected in the next year compared to the current price of 8.6. Check the ELICIO THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is ELICIO THERAPEUTICS INC worth?
ELICIO THERAPEUTICS INC (ELTX) has a market capitalization of 137.60M USD. This makes ELTX a Micro Cap stock.
How many employees does ELICIO THERAPEUTICS INC have?
ELICIO THERAPEUTICS INC (ELTX) currently has 32 employees.
What are the support and resistance levels for ELICIO THERAPEUTICS INC (ELTX) stock?
ELICIO THERAPEUTICS INC (ELTX) has a support level at 9.19 and a resistance level at 9.99. Check the full technical report for a detailed analysis of ELTX support and resistance levels.
Should I buy ELICIO THERAPEUTICS INC (ELTX) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of ELTX, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of ELTX, evaluating the profitability, health, valuation and growth aspects
- ELICIO THERAPEUTICS INC (ELTX) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- ELICIO THERAPEUTICS INC (ELTX) Sales and EPS estimates to see what analysts future expectations are.
- ELICIO THERAPEUTICS INC (ELTX) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- ELICIO THERAPEUTICS INC (ELTX) Insider and Institutional Ownership to learn about the owners and their transactions.
- ELICIO THERAPEUTICS INC (ELTX) Stock Chart to make your own analysis
- ELICIO THERAPEUTICS INC (ELTX) Latest news and press-releases to stay up to date.
Does ELICIO THERAPEUTICS INC (ELTX) stock pay dividends?
ELTX does not pay a dividend.
When does ELICIO THERAPEUTICS INC (ELTX) report earnings?
ELICIO THERAPEUTICS INC (ELTX) will report earnings on 2025-11-11.
What is the Price/Earnings (PE) ratio of ELICIO THERAPEUTICS INC (ELTX)?
ELICIO THERAPEUTICS INC (ELTX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.92).
What is the Short Interest ratio of ELICIO THERAPEUTICS INC (ELTX) stock?
The outstanding short interest for ELICIO THERAPEUTICS INC (ELTX) is 4.58% of its float. Check the ownership tab for more information on the ELTX short interest.
ELTX Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to ELTX. When comparing the yearly performance of all stocks, ELTX is one of the better performing stocks in the market, outperforming 96.1% of all stocks.
ELTX Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to ELTX. ELTX scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
ELTX Financial Highlights
Over the last trailing twelve months ELTX reported a non-GAAP Earnings per Share(EPS) of -3.92. The EPS increased by 41.34% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -182.21% | ||
| ROE | -575.93% | ||
| Debt/Equity | 0 |
ELTX Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to ELTX. The Buy consensus is the average rating of analysts ratings from 8 analysts.